Vertical Farming for Medicinal Cannabis Market Size & Share 2026-2035

Vertical Farming for Medicinal Cannabis Market Size

The vertical farming for medicinal cannabis market was valued at USD 331 million in 2025 and is projected to reach USD 1.57 billion by 2035, expanding at a CAGR of 16.9% over 2026–2035. According to the latest report published by Global Market Insights Inc., market revenue reaches USD 387 million in 2026.

The addressable market centers on controlled, indoor, multi-tier cultivation systems and the hardware, software, and services required to produce pharmaceutical-grade medicinal cannabis. Growth reflects a regulatory change in which reproducibility, traceability, and environmental control increasingly determine access to pharmaceutical channels rather than merely differentiating premium operators. The commercial center of gravity is moving from standalone cultivation equipment toward validated production systems that link environmental controls, digital records, and GMP-oriented operating procedures.

The market measured USD 207 million in 2022, USD 242 million in 2023, USD 283 million in 2024, and USD 331 million in 2025. The historic and forecast CAGR is 16.9%. Estimates use bottom-up sizing of cultivation infrastructure, automation, software, and associated services deployed in medicinal cannabis production, triangulated against regional regulatory pathways, facility activity, and technology-provider participation. The scope excludes uncontrolled outdoor production and conventional single-layer cultivation that does not meet the vertical indoor controlled-environment definition.

Europe supplies the principal demand anchor. Germany’s MedCanG became effective on April 1, 2024 and established a domestic licensed-cultivation pathway, while the European Medicines Agency’s revised Good Agricultural and Collection Practice guidance strengthens the documentation expectations surrounding medicinal-plant production. ^{[1]Federal Ministry of Health, Germany - Medicinal Cannabis Act and Cannabis Policy Materials - bundesgesundheitsministerium.de} The immediate effect is demand for facilities capable of maintaining auditable environmental records and batch controls. The second-order effect is procurement concentration around suppliers that can document the performance of lighting, irrigation, sensing, air handling, and cultivation-management systems within a GMP operating model.

Hardware remains the largest component at USD 196.9 million, or 59.5% of 2025 revenue. Software accounts for USD 71.2 million, or 21.5%, and advances at 19.4% CAGR, above the market average. That premium reflects the conversion of cultivation data from an efficiency tool into a compliance asset. Services account for USD 62.9 million, or 19.0%, as facility design, system integration, validation support, and maintenance remain necessary for new GMP-oriented builds.

Key Drivers

Germany’s domestic cultivation pathway and the broader European documentation environment place compliance-capable facilities closer to pharmaceutical distribution channels. ^{[2]European Medicines Agency - Good Agricultural and Collection Practice Guidance - ema.europa.eu} The mechanism is operational: controlled cultivation provides continuous records for temperature, humidity, irrigation, lighting, sanitation, and harvest lots. That favors investments in sealed rooms, validated water systems, environmental monitoring, and traceability software. Commercially, those investments convert regulatory capability into access to higher-value institutional and pharmacy channels.

Pharmaceutical purchasers require repeatable cannabinoid profiles and contamination controls. Hydroponic and aeroponic systems provide the controllable root-zone, nutrient, and environmental inputs needed to support that objective. The buyer is not purchasing vertical capacity in isolation; the buyer is purchasing confidence that successive batches can meet an agreed specification. This shifts value toward integrated sensor, automation, and compliance platforms.

LED efficiency and climate-control improvements lower an operator’s exposure to the energy intensity of indoor production. Fluence’s 2025 SPYDR 3 and VYPR 4 introductions illustrate continued product development in cannabis horticultural lighting. ^{[3]Fluence - SPYDR 3 and VYPR 4 Cannabis Horticulture Lighting Announcements - fluence-led.com} Lower energy demand does not eliminate electricity exposure, but it improves the economics of facilities that can sustain pharmaceutical production requirements. The operational implication is longer equipment-refresh cycles tied to measured efficiency and uniformity rather than simple lamp replacement.

Colombia, Thailand, and South Africa add a longer-horizon export opportunity because controlled cultivation can combine lower-cost production conditions with pharmaceutical certification pathways. Colombia’s medicinal-cannabis framework and South Africa’s licensing activity provide the regulatory basis for export-oriented projects. ^{[4]Ministry of Trade, Industry and Tourism, Colombia - Medicinal Cannabis Export Framework - mincit.gov.co} These markets will compete on certified supply reliability rather than agricultural cost alone. European import requirements therefore remain the reference point for facility design.

Key Restraints

Purpose-built GMP facilities require more than racks and lights. They need validated air handling, water treatment, access controls, cleaning procedures, documentation workflows, and operating protocols. The resulting capital burden limits the number of companies able to own their own production infrastructure. Contract cultivation therefore serves as a capital-allocation response as well as a manufacturing model.

Energy use creates a recurring commercial constraint. Lighting, dehumidification, HVAC, and environmental management must operate consistently even when utility prices are volatile. The constraint is sharper in high-cost power markets and at facilities that lack renewable generation, storage, or recent lighting upgrades. It also creates an incentive for suppliers to sell documented operating efficiency rather than nominal fixture output.

Licensing multiplies the workload for producers serving several countries. The operator must align cultivation records, product specifications, national requirements, and export documentation. Canada’s Cannabis Regulations and Australia’s TGA-supervised market show how national requirements can coexist with international GMP expectations. ^{[7]Therapeutic Goods Administration - Australian Therapeutic Goods Regulation - tga.gov.au} Multijurisdictional capability is consequently a barrier to entry and a source of defensibility for established operators.

Vertical Farming for Medicinal Cannabis Market Segment Analysis

By Growing Technology

Hydroponics leads the market with USD 205.2 million and 62% share in 2025, expanding at a 15.9% CAGR through 2035. The category includes deep water culture, nutrient film technique, ebb and flow or flood and drain systems, and drip irrigation. Its installed base benefits from established operating knowledge, mature nutrient-delivery protocols, and compatibility with controlled-room design. In pharmaceutical cultivation, that maturity reduces the burden of proving repeatability across production cycles.

Hydroponic systems still face a strategic tradeoff between recirculating designs, which improve nutrient and water efficiency, and run-to-waste approaches, which can simplify contamination-control procedures. Pipp Horticulture’s mobile vertical racking systems and AROYA’s TEROS sensors, IRRIGAIT AI, and AUTOMAIT AI provide examples of infrastructure and control layers that can improve canopy utilization and root-zone visibility. ^{[8]Pipp Horticulture - Mobile Vertical Grow System and Company Materials - pipphorticulture.com} Hydroponics will retain its revenue lead because it is the most familiar architecture for large licensed producers. Its below-market growth rate, however, signals a gradual move toward higher-performance alternatives in premium applications.

Aeroponics reaches USD 86.1 million in 2025 and holds 26% share, with a 19.2% CAGR through 2035. High-pressure aeroponics is the principal commercial configuration, while low-pressure systems remain relevant to cloning and vegetative stages. Root-zone oxygenation and fine control over nutrient mist support the segment’s appeal where cannabinoid and terpene consistency has commercial value. AEssense’s AEtrium-2.1 SmartFarm, AEtrium-4, and Guardian Grow Manager demonstrate how aeroponic platforms combine cultivation architecture with automation.

The economics of aeroponics depend less on a generic yield claim than on whether the operator can monetize a more predictable pharmaceutical specification. That makes the technology more attractive to contracts with differentiated cannabinoid requirements than to bulk-volume supply. Urban Crop Solutions’ customized vertical-farm engineering model and AEssense’s European medicinal-cannabis activity show how the category is entering facility-development decisions rather than remaining a pilot option. ^{[9]Urban Crop Solutions - Customized Vertical Farming Engineering Solutions - urbancropsolutions.com} The segment’s higher growth rate will raise its role in newly commissioned GMP facilities through 2030.

Aquaponics accounts for USD 39.7 million, or 12% of 2025 revenue, and advances at the market-average 16.9% CAGR. The technology links fish-aquaculture nutrient streams with plant cultivation and has relevance for operators emphasizing integrated resource systems. Its commercial role remains narrower because pharmaceutical validation can be more complex when biological inputs add process variability. In Colombia and Thailand, aquaponics may appeal to export-oriented operators pursuing sustainability positioning, but it does not displace hydroponics as the baseline pharmaceutical cultivation architecture.

By Component

Hardware accounts for USD 196.9 million, or 59.5% of 2025 revenue, and grows at 15.9% CAGR. The category includes racking and shelving, LED lighting, HVAC and climate control, irrigation and nutrient delivery, sensors and IoT monitoring, water purification, and security and access control. Hardware receives the largest initial capital allocation because a GMP-grade indoor facility cannot operate without physical environmental containment and validated process equipment.

Fluence’s SPYDR 3 and VYPR 4 lighting systems, SANlight’s STIXX-Series development with Cree LED, and Pipp’s mobile racking and VAS 2.0 airflow collaboration illustrate the interdependence of light distribution, canopy density, and air movement. A hardware purchase increasingly carries a documentation requirement: buyers need proof of maintainability, integration capability, and performance within the cultivation room. This protects established suppliers but also places price pressure on undifferentiated equipment categories.

Software generates USD 71.2 million in 2025 and has the fastest component CAGR at 19.4%. Farm-management software, AI and machine-learning monitoring platforms, environmental-control software, and compliance and traceability tools constitute the segment. Growlink’s Growlink OS, Blueprints, Nova AI, Co-Pilot, and LINKS device connect climate, lighting, and irrigation controls across multi-zone environments. AROYA’s sensor-to-irrigation stack and its partnership with CANNAVIGIA align cultivation data with EU-GMP documentation and traceability workflows.

The software value proposition is changing from operational visibility to evidence generation. A record that links inputs, environmental conditions, and batch identity can reduce manual reconciliation during inspection preparation. That capability creates switching costs once a platform is embedded in standard operating procedures. Software will therefore capture a rising portion of lifetime facility spending even as it remains smaller than the installed hardware base.

Services contribute USD 62.9 million in 2025 and grow at 16.9% CAGR. Facility design and engineering, installation, integration, GMP and GACP consulting, maintenance, and managed services all sit within the category. Urban Crop Solutions bundles design, hardware, software integration, and consulting for customized projects. Services matter because pharmaceutical-grade facilities require the coordination of multiple technology layers and local regulatory requirements. Demand persists after commissioning through maintenance, validation updates, and operating-process revisions.

By Facility Structure

Building-based facilities account for USD 213.8 million, or 64.6% of 2025 revenue, and advance at 17.7% CAGR. Purpose-built GMP sites support cleanroom-grade HVAC, controlled water systems, sealed cultivation areas, and workflows designed around compliance. Repurposed warehouses can lower construction costs, but they may require greater adaptation to meet environmental and documentation standards.

Bedrocan operates two Netherlands facilities with combined capacity of up to 7,500 kg per year and inaugurated a 2,300 kg-per-year Denmark facility in 2025. ^{[11]Bedrocan International - Company, Facility, and Quality Standards Materials - bedrocan.com} Little Green Pharma operates a 21,500 m² cultivation facility and a 4,000 m² GMP manufacturing site in Denmark. DEMECAN’s 32,000 m² Cannabis Campus incorporates sealed, climate-controlled rooms and targets approximately 4,000 kg per year of cultivation capacity. These projects demonstrate that building-based assets serve both production volume and regulatory credibility.

Container-based facilities generate USD 117.2 million, or 35.4% of 2025 revenue, and grow at 14.9% CAGR. Standard 20-foot and 40-foot units and multi-container installations offer shorter deployment cycles, modularity, and location flexibility. The structure is most relevant in Latin America, MEA, and Asia Pacific where operators may stage capacity additions or establish a domestic GMP pathway before committing to a full purpose-built site. The tradeoff is that container systems may face limitations in large-volume production and pharmaceutical workflow integration.

By End-User Type

Licensed pharmaceutical producers account for USD 215.2 million, or 65.0% of 2025 revenue, and expand at 16.0% CAGR. Large-scale producers require high-value systems because they operate institutional supply contracts and must document quality across substantial production volumes. InterCure Ltd / Canndoc operates a 355,000 sq ft GMP-certified cultivation facility, while its FY2024 revenue reached NIS 239 million. Curaleaf International adds certified cultivation and distribution capability across several countries.

This segment rewards scale only when scale is governed. Larger sites create a greater need for consistent environmental zones, digital batch records, and controlled material flows. Bedrocan’s long-standing Dutch medicinal-cannabis activity and standardized product portfolio illustrate how validated operations can become a reference point for buyers and regulators. Licensed producers will remain the largest demand group because they are the most direct purchasers of complete production infrastructure.

Contract cultivation organizations generate USD 54.6 million, or 16.5% of 2025 revenue, and post the fastest end-user CAGR at 20.0%. The CCO model allows pharmaceutical companies to source controlled cultivation without assuming full ownership of a GMP facility. Avextra’s cultivation and manufacturing operations across Germany and Portugal represent a vertically integrated, CCO-adjacent model that combines cultivation with pharmaceutical processing.

The CCO model changes the investment decision from building a site to securing qualified capacity. This broadens the customer base for service providers, software vendors, and validated equipment suppliers because CCOs must serve multiple clients under rigorous documentation requirements. The longer-term implication is a division of labor between product owners and specialized cultivation operators.

Academic and research institutions account for USD 33.1 million, or 10.0%, of 2025 revenue. Government and state-licensed cultivators represent USD 28.1 million, or 8.5%. These groups deploy controlled systems for cultivar research, clinical material, national programs, and early-stage supply development. South Africa’s expanded licensing framework illustrates the role of government authorization in creating new pharmaceutical cultivation demand. ^{[5]South African Health Products Regulatory Authority - Medicinal Cannabis Licensing Framework - sahpra.org.za} Their spending patterns are smaller than those of licensed producers but can establish technical standards that influence commercial procurement.

Vertical Farming for Medicinal Cannabis Market Regional Analysis

North America

North America accounts for USD 29.9 million, or 9.0% share, and grows at 14.9% CAGR. The United States faces a federal Schedule I constraint that limits institutional pharmaceutical cultivation at scale. Canada provides the region’s clearer regulated pathway through the Cannabis Regulations. ^{[6]Government of Canada - Cannabis Regulations (SOR/2018-144) - canada.ca} Curaleaf’s acquisition of Northern Green Canada in April 2024 demonstrates the strategic value of Canadian EU-GMP indoor production for export supply. North America’s installed technology base remains important, but federal fragmentation limits its growth rate relative to European markets.

Europe

Europe leads with USD 148.9 million in 2025, representing 45.0% share, and grows at 17.0% CAGR through 2035. Germany, the Netherlands, France, the United Kingdom, Spain, Italy, and Denmark form the core regional market. Germany’s MedCanG provides the strongest recent domestic catalyst, while the EMA’s GACP framework creates a common documentation direction for pharmaceutical supply. Europe’s constraint is the high cost and validation burden of maintaining controlled facilities, but those same requirements protect qualified suppliers from low-specification competition.

Tilray Deutschland GmbH operates as the commercial entity alongside cultivation subsidiary Aphria RX GmbH at the 6,000 m² EU-GMP facility in Neumünster. Aphria RX received a MedCanG cultivation license in July 2024, and Tilray Deutschland won Luxembourg’s national medicinal-cannabis supply tender in January 2025. DEMECAN’s July 2024 MedCanG license and sealed indoor campus reinforce Germany’s role as a domestic production market. In Denmark, Little Green Pharma’s facility provides a northern European production base for the German market.

Asia Pacific

Asia Pacific reaches USD 64.1 million in 2025, or 19.4% share, and advances at 17.1% CAGR. Australia supplies the clearest pharmaceutical production case, while Thailand offers an emerging regulated cultivation pathway. Cann Group completed commissioning of its 34,000 m² GMP-certified indoor Mildura facility in February 2024 under TGA oversight. Its operational facility remains strategically relevant, although a completed debt restructuring and FY2025 loss underscore that capital constraints can limit future investment.

Thailand’s GMP pathway gives the country a role in export-oriented cultivation, while China, India, Japan, and South Korea remain in the regional coverage set with more limited medicinal-cannabis market development. The region’s opportunity is to combine controlled production with export compliance. Its constraint is uneven regulation, which makes country selection and certification sequencing central to project economics.

Latin America

Latin America contributes USD 48.1 million in 2025, or 14.5% share, and grows at 16.6% CAGR. Brazil, Mexico, Argentina, and Colombia form the regional coverage base. Colombia’s Law 1787/2016 and Resolution 315/2020 establish an export-oriented medicinal-cannabis framework that supports investment in controlled, certified production. Lower-cost production conditions can improve competitiveness, yet successful projects still need GMP documentation and buyer acceptance in destination markets. Container-based and modular facility structures are therefore more relevant in the region than in Europe’s highest-regulation markets.

Middle East and Africa

Middle East and Africa totals USD 40.0 million in 2025, or 12.1% share, and posts the highest regional CAGR at 17.9%. Israel and South Africa are the most operationally relevant markets, while Saudi Arabia and the UAE remain in the regional coverage base. InterCure Ltd / Canndoc has export authorizations across more than 40 countries, positioning Israel as a production and export hub. South Africa’s SAHPRA licensing expansion supports the formation of new GMP-oriented cultivation capacity. The regional advantage is export potential; the regional constraint is the need to translate licensing into qualified supply relationships.

Vertical Farming for Medicinal Cannabis Market Share & Competitive Landscape

The market is moderately fragmented. The top five players collectively held approximately 35% of 2025 revenue. Fluence (Signify) held approximately 7%, InterCure Ltd / Canndoc held approximately 6%, and Pipp Horticulture held approximately 5%. The remaining top-five positions and the broader market include regional producers, technology suppliers, and specialized cultivation firms. Agrify’s former Vertical Farming Unit business was divested to CP Acquisitions LLC on December 31, 2024; its former approximate 9% share is carried in Others for the 2025 base year rather than assigned to Growlink.

Competition takes place across two linked tiers. Technology providers compete on validated lighting, racking, cultivation controls, sensing, and facility integration. Cultivation operators compete on GMP status, capacity, product standardization, export permissions, and pharmaceutical-channel relationships. The strongest competitive positions connect these tiers, because a producer’s compliance record is shaped by the reliability and traceability of its technology stack.

Growlink provides the cultivation intelligence layer through Growlink OS, Blueprints, Nova AI, Co-Pilot, and the LINKS IoT control device, which began commercial shipping in March 2025. Its differentiation lies in interoperability across climate, lighting, and irrigation zones rather than ownership of physical cultivation hardware. DEMECAN is Germany’s independent domestic producer, with sealed vertical indoor rooms, a 32,000 m² campus, and a MedCanG cultivation license. Urban Crop Solutions competes as a turnkey system integrator through customized engineering, hardware, software integration, and consulting.

Fluence leverages Signify’s lighting scale and its SPYDR 3 and VYPR 4 cannabis horticultural products. AROYA by Addium links TEROS root-zone sensors with AI irrigation tools and the CANNAVIGIA compliance partnership. AEssense provides AEtrium aeroponic systems and Guardian Grow Manager automation for high-density cultivation configurations. Pipp Horticulture supplies mobile racking and airflow infrastructure that improves productive canopy utilization in constrained GMP rooms.

Among licensed producers, Little Green Pharma combines Danish cultivation and manufacturing with European sales. Tilray Deutschland and Aphria RX combine commercial distribution and licensed cultivation in Germany. Avextra integrates Portuguese cultivation with German pharmaceutical manufacturing. InterCure combines Israeli GMP production, pharmacy operations, and export coverage. Cann Group operates a TGA GMP Australian facility but faces financial constraints after a debt restructuring. Bedrocan supplies the Dutch medicinal-cannabis program and added a Denmark facility in 2025. SANlight develops precision LED lighting and partnered with Cree LED for its STIXX-Series. ^{[10]Cree LED - Cree LED and SANlight Horticulture Lighting Partnership - cree-led.com} Curaleaf International combines EU-GMP cultivation assets with multinational processing and distribution.

Growlink replaces Agrify in the active company list following Agrify’s vertical-farming exit. AROYA replaces Heliospectra following Heliospectra’s cannabis-segment exit. DEMECAN replaces Village Farms because the approved scope requires multi-tier vertical indoor medicinal-cannabis relevance. Cann Group remains active and TGA GMP certified, but its financial stress limits confidence in near-term expansion capacity. Tilray Deutschland GmbH is the commercial entity, while Aphria RX GmbH is the licensed cultivation entity at the Neumünster site.

Recent Industry Developments

Apr 2025: AEssense exhibited with Endo Canna at ICBC Berlin and announced expansion activity in Germany and the United Kingdom. The event signals continued commercial attention to aeroponic, multi-tier medicinal-cannabis cultivation systems in European markets.

Mar 2025: Growlink began commercial shipping of the LINKS IoT monitoring and control device. The product expands the set of dedicated tools capable of coordinating climate, lighting, and irrigation across vertical cultivation zones.

Jan 2025: Tilray Deutschland GmbH won a tender to supply Luxembourg’s national medicinal-cannabis program. The award demonstrates how certified German cultivation and distribution capability can translate into sovereign procurement access.

Dec 2024: AROYA announced AUTOMAIT AI and related irrigation tools following its CANNAVIGIA partnership. The development links cultivation automation with the broader compliance-data workflow needed by medicinal-cannabis operators.

Jul 2024: DEMECAN received a MedCanG cultivation license, and Aphria RX received cultivation and trading licenses in Germany. These actions expand the domestic cultivation base under Germany’s post-MedCanG framework.